Efficacy and safety of vancomycin versus 13 alternatives in MRSA-confirmed skin and soft tissue infections: a meta-analysis of 39 randomized controlled trials
Despite the growth of newer anti-MRSA agents, vancomycin remains clinically comparable for MRSA-confirmed SSTI, with apparent microbiological advantages of alternatives tempered by potential publication bias. Varying safety and pharmacological profiles of these agents emphasize the importance of individualized treatment selection.
Institutions
- Chung-Ang University (KR)
Publication Details
- Journal
- Infection
- Published
- 2026-03-24
- DOI
- https://doi.org/10.1007/s15010-026-02745-7
- Primary Topic
- Antimicrobial Resistance in Staphylococcus
- Type
- article
- Field-Weighted Citation Impact
- 0.00